Clinical Trial Update: Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating donor-derived multi-virus-specific cytotoxic T-lymphocytes for relapsed/refractory neuroblastoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Snippet

Sponsor: Children's Mercy Hospital Kansas City | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2019-07-23